Our findings reveal expression of ST6GAL1 alters sialoglycan patterns in prostate cancer cells, and in line with the literature,72,73 we find ST6GAL1 specifically regulates sialoglycans that engage Siglec-2 (CD22) and Siglec 3 (CD33) (Fig. 5a–e and Supplementary Fig. S7). Here, CD22 is linked to prostate carcinoma.